Recombinant Human Integral membrane protein 2B (ITM2B), Truncated

Cat.No	ACP18837	Target Name	ITM2B
Form	Lyophilized powder	Expression System	Custom Production. Please inquire and provide the desire expression system.
Protein Length	Partial	Purity	>85% (SDS-PAGE)
Storage Buffer	5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Cat.No

ACP18837

Target Name

ITM2B

Form

Lyophilized powder

Expression System

Custom Production. Please inquire and provide the desire expression system.

Protein Length

Partial

Purity

>85% (SDS-PAGE)

Storage Buffer

5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Target Species	Human	Uniprot ID	Q9Y287

Background Information

Uniprot Id

Q9Y287
Target Species

Human
Target Name

ITM2B
Target Full Name

Integral membrane protein 2B
Target Function

Plays a regulatory role in the processing of the amyloid-beta A4 precursor protein (APP) and acts as an inhibitor of the amyloid-beta peptide aggregation and fibrils deposition. Plays a role in the induction of neurite outgrowth. Functions as a protease inhibitor by blocking access of secretases to APP cleavage sites.; Mature BRI2 (mBRI2) functions as a modulator of the amyloid-beta A4 precursor protein (APP) processing leading to a strong reduction in the secretion of secretase-processed amyloid-beta protein 40 and amyloid-beta protein 42.; Bri23 peptide prevents aggregation of APP amyloid-beta protein 42 into toxic oligomers.
Target Involvement

Cerebral amyloid angiopathy, ITM2B-related 1 (CAA-ITM2B1); Cerebral amyloid angiopathy, ITM2B-related 2 (CAA-ITM2B2); Retinal dystrophy with inner retinal dysfunction and ganglion cell abnormalities (RDGCA)
Target Subcellular Location

[Integral membrane protein 2B]: Golgi apparatus membrane; Single-pass type II membrane protein.; [Bri23 peptide]: Secreted.; [BRI2C, soluble form]: Secreted.
Target Protein Families

ITM2 family
Target Tissue Specificity

Ubiquitous. Expressed in brain.
Target Synonyms

ABRI; ABri/ADan amyloid peptide; BRI 2; BRI; BRI2; BRICD 2B; BRICD2B; BRICHOS domain containing 2B; E25B; E3 16; E3-16; FBD; imBRI2; Immature BRI2; Integral membrane protein 2B; ITM 2B; ITM2B; ITM2B_HUMAN; Protein E25B; RDGCA; Transmembrane protein BRI
Target Background

Amyloid precursor proteins are processed by beta-secretase and gamma-secretase to produce beta-amyloid peptides which form the characteristic plaques of Alzheimer disease. This gene encodes a transmembrane protein which is processed at the C-terminus by furin or furin-like proteases to produce a small secreted peptide which inhibits the deposition of beta-amyloid. Mutations which result in extension of the C-terminal end of the encoded protein, thereby increasing the size of the secreted peptide, are associated with two neurogenerative diseases, familial British dementia and familial Danish dementia.

Recombinant Human Integral membrane protein 2B (ITM2B), Truncated

Specifications

Immunogen Information

Inquire Recombinant Human Integral membrane protein 2B (ITM2B), Truncated Now

Related Products